Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 117
Filtrar
Más filtros

Intervalo de año de publicación
1.
Int J Mol Sci ; 25(8)2024 Apr 13.
Artículo en Inglés | MEDLINE | ID: mdl-38673900

RESUMEN

It is known that many diabetic patients experience testicular atrophy. This study sought to investigate the effect of 4-hexylresorcinol (4HR) on testicular function in rats with streptozotocin (STZ)-induced diabetes, focusing on testicular weight, sperm motility, histological alterations, and serum testosterone levels to understand the efficacy of 4HR on testes. Our findings reveal that 4HR treatment significantly improves testicular health in diabetic rats. Notably, the STZ group exhibited a testicular weight of 1.22 ± 0.48 g, whereas the STZ/4HR group showed a significantly enhanced weight of 1.91 ± 0.26 g (p < 0.001), aligning closely with the control group's weight of 1.99 ± 0.17 g and the 4HR group's weight of 2.05 ± 0.24 g, indicating no significant difference between control and 4HR groups (p > 0.05). Furthermore, the STZ/4HR group demonstrated significantly improved sperm motility compared to the STZ group, with apoptotic indicators notably reduced in the STZ/4HR group relative to the STZ group (p < 0.05). These results underscore the therapeutic potential of 4HR for maintaining testicular function under diabetic conditions.


Asunto(s)
Diabetes Mellitus Experimental , Hexilresorcinol , Motilidad Espermática , Testículo , Testosterona , Animales , Masculino , Diabetes Mellitus Experimental/tratamiento farmacológico , Testículo/efectos de los fármacos , Testículo/metabolismo , Testículo/patología , Ratas , Motilidad Espermática/efectos de los fármacos , Testosterona/sangre , Hexilresorcinol/farmacología , Hexilresorcinol/uso terapéutico , Apoptosis/efectos de los fármacos , Estreptozocina , Ratas Sprague-Dawley , Tamaño de los Órganos/efectos de los fármacos
2.
Bull Exp Biol Med ; 176(4): 466-471, 2024 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-38488964

RESUMEN

We studied the possibility of using 4-hexylresorcinol to increase the efficiency of anti-mycobacterial chemotherapy. In an in vitro experiment, 4-hexylresorcinol increased the efficiency of rifampicin, kanamycin, and isoniazid against Mycobacterium smegmatis by 3-5 times. Experiments in sanitation of BALB/c mice infected with M. smegmatis showed the best efficacy of the isoniazid and 4-hexylresorcinol combination in comparison with isoniazid monotherapy. The growth-inhibiting activity of the combination of antibiotic rifabutin with 4-hexylresorcinol was shown on 6 strains of M. tuberculosis. A 2-fold decrease in the minimum inhibitory concentration of this antibiotic in the presence of half-minimum inhibitory concentration of 4-hexylresorcinol was demonstrated for monoresistant strain M. tuberculosis 5360/42Hr. On the mouse model of experimental tuberculosis caused by M. tuberculosis H37Rv, a 5-fold decrease in lung contamination and more rapid complete cure were achieved in animals treated with the combination of rifabutin and 4-hexylresorcinol in comparison with rifabutin monotherapy.


Asunto(s)
Hexilresorcinol , Mycobacterium tuberculosis , Tuberculosis , Animales , Ratones , Antituberculosos/farmacología , Antituberculosos/uso terapéutico , Isoniazida/farmacología , Isoniazida/uso terapéutico , Hexilresorcinol/farmacología , Rifabutina/farmacología , Rifabutina/uso terapéutico , Tuberculosis/tratamiento farmacológico , Pruebas de Sensibilidad Microbiana , Adyuvantes Inmunológicos/uso terapéutico
3.
Int J Mol Sci ; 24(19)2023 Sep 28.
Artículo en Inglés | MEDLINE | ID: mdl-37834163

RESUMEN

Biocidal coatings have been used in biomedicine, cosmetology and the food industry. In this article, the coatings are described as being composed of non-stoichiometric polycomplexes, products of electrostatic coupling of two commercial biodegradable ionic polymers, anionic sodium alginate and cationic quaternized hydroxyethyl cellulose ethoxylate. Non-stoichiometric polycomplexes with a 5-fold excess of the cationic polymer were used for immobilizing hydrophobic biocidal 4-hexylresorcinol (HR). Being dispersed in water, the polycomplex particles were capable of absorbing a tenfold excess of HR in relation to the polycation. After deposition onto the plastic surface and drying, the aqueous polycomplex-HR composite formulation forms a transparent homogeneous coating, which swells slightly in water. The interpolyelectrolyte complex (IPEC) is substantially non-toxic. The incorporation of HR in the IPEC imparts antimicrobial activity to the resulting composite, in both aqueous solutions and coatings, against Gram-negative and Gram-positive bacteria and yeast. The polysaccharide-based polycomplexes with embedded HR are promising for the fabrication of biocidal films and coatings.


Asunto(s)
Hexilresorcinol , Agua , Agua/química , Polímeros/farmacología , Polímeros/química
4.
Int J Mol Sci ; 24(1)2022 Dec 21.
Artículo en Inglés | MEDLINE | ID: mdl-36613594

RESUMEN

Silk sericin is a degumming product used by the silk industry. The degumming process can affect the protein structure and molecular weight of silk sericin. The present study examined how pretreatment with 4-hexylresorcinol (4HR) affects the biomedical properties of silk sericin. Before the degumming process, silkworm cocoons were treated with 4HR solution. The protein structure of the final degumming product was evaluated by Fourier transform infrared spectroscopy (FT-IR) and scanning electron microscopy. Untreated silk sericin (S) and silk sericin pretreated with 4HR (S+4HR) were added to RAW264.7 cells, and the expression of BMP-2 was determined. The bone-regenerating capacity of S+4HR was evaluated using the critical-sized rat calvarial defect model. Compared with S, S+4HR showed an increase in ß-sheet structures. Administration of S+4HR to RAW264.7 cells increased expression of BMP-2, mainly via the TLR-mediated signaling pathway. Bone volume, as measured by micro-computerized tomography, was significantly greater in the S+4HR group than in the S, gelatin alone, and unfilled control groups (p < 0.05 each). Expression of BMP-2 and runx2 in tissue specimens was significantly higher following treatment with S+4HR than with S (p < 0.05). Taken together, these findings show that 4HR pretreatment before the degumming process increased the ß-sheet structure of silk sericin, as well as inducing BMP-2 expression and bone regeneration ability.


Asunto(s)
Bombyx , Hexilresorcinol , Sericinas , Ratas , Animales , Sericinas/química , Hexilresorcinol/farmacología , Espectroscopía Infrarroja por Transformada de Fourier , Conformación Proteica en Lámina beta , Seda/química , Bombyx/metabolismo
5.
Int J Cosmet Sci ; 44(1): 103-117, 2022 Feb.
Artículo en Inglés | MEDLINE | ID: mdl-34958693

RESUMEN

OBJECTIVES: To demonstrate the synergistic effect of 4-hexylresorcinol (4-HR) with niacinamide in boosting anti-melanogenic efficacy in vitro and establish the in vivo efficacy and safety of the combination in a human trial. METHODS: Primary human epidermal melanocytes and 3D pigmented skin equivalents were treated with 4-HR, niacinamide, and their combinations for their effect on pigmentation. This was followed by a randomized, double-blind, split-face clinical study in Chinese subjects, and effects on skin tone, hyperpigmentation, fine lines and wrinkles, hydration, and skin firmness were measured for a 12-week study period. RESULTS: In vitro tyrosinase enzyme activity studies showed that 4-HR is one of the most potent tyrosinase inhibitors. The combination of 4-HR and niacinamide showed a synergistic reduction in melanin production in cultured melanocytes and lightened the 3D skin equivalent model. In vitro as well as in the human trial, the combination of 4-HR and niacinamide showed significantly improved efficacy over niacinamide alone on hyperpigmentation spots as measured by L*, the visual appearance of fine lines and wrinkles in crow's feet and perioral area and skin firmness, with no product-related adverse events. CONCLUSIONS: A formulation containing a combination of 4-HR and niacinamide delivered superior skin tone and anti-ageing benefits significantly better than niacinamide alone with no adverse events. This study demonstrates that a product designed to affect multiple pathways of melanogenesis, inflammation, and ageing may provide an additional treatment option, beyond hydroquinone and retinoids, for hyperpigmentation and ageing.


OBJECTIFS: Démontrer l'effet synergique du 4-hexylrésorcinol (4-HR) associé au niacinamide pour stimuler in vitro l'efficacité antimélanogène, et établir l'efficacité et la sécurité d'emploi in vivo de cette association dans un essai chez l'homme. MÉTHODES: Des mélanocytes épidermiques humains primaires et des équivalents cutanés pigmentés en 3D ont été traités avec du 4-HR, du niacinamide et leurs combinaisons pour leur effet sur la pigmentation. Ceci a été suivi d'une étude clinique randomisée, en double aveugle en hémi-visage chez des sujets chinois, et les effets sur le teint, l'hyperpigmentation, les rides et ridules, l'hydratation et la fermeté de la peau ont été mesurés pendant une durée d'étude de 12 semaines. RÉSULTATS: Les études in vitro sur l'activité enzymatique de la tyrosinase ont montré que le 4-HR est l'un des inhibiteurs de la tyrosinase les plus puissants. L'association du 4-HR et du niacinamide a montré une réduction synergique de la production de mélanine dans les mélanocytes de culture et donné de la luminosité au modèle cutané 3D équivalent. Également in vitro avec l'étude chez l'homme, l'association du 4-HR et du niacinamide a fait ressortir une efficacité significativement plus élevée qu'avec le niacinamide seul sur les taches d'hyperpigmentation mesurées par L*, l'aspect visuel des rides et ridules des pattes d'oie et de la zone périorale, et la fermeté de la peau, sans événements indésirables liés au produit. CONCLUSIONS: Une formulation contenant une association de 4-HR et de niacinamide a permis d'obtenir un teint et un effet anti-âge nettement supérieurs à ceux du niacinamide seul, sans événements indésirables. Cette étude démontre qu'un produit conçu pour toucher plusieurs voies de mélanogenèse, d'inflammation et de vieillissement peut constituer une nouvelle option thérapeutique, au-delà de l'hydroquinone et des rétinoïdes, pour l'hyperpigmentation et le vieillissement.


Asunto(s)
Hexilresorcinol , Hiperpigmentación , Envejecimiento , Hexilresorcinol/uso terapéutico , Humanos , Hiperpigmentación/tratamiento farmacológico , Niacinamida/farmacología , Pigmentación de la Piel
6.
Int J Mol Sci ; 22(16)2021 Aug 19.
Artículo en Inglés | MEDLINE | ID: mdl-34445640

RESUMEN

4-Hexylresorcinol (4HR) has been used as a food additive, however, it has been recently demonstrated as a Class I histone deacetylase inhibitor (HDACi). Unlike other HDACi, 4HR can be taken through foods. Unfortunately, some HDACi have an influence on craniofacial growth, therefore, the purpose of this study was to evaluate the effects of 4HR on craniofacial growth. Saos-2 cells (osteoblast-like cells) were used for the evaluation of HDACi and its associated activities after 4HR administration. For the evaluation of craniofacial growth, 12.8 mg/kg of 4HR was administered weekly to 4 week old rats (male: 10, female: 10) for 12 weeks. Ten rats were used for untreated control (males: 5, females: 5). Body weight was recorded every week. Serum and head samples were collected at 12 weeks after initial administration. Craniofacial growth was evaluated by micro-computerized tomography. Serum was used for ELISA (testosterone and estrogen) and immunoprecipitation high-performance liquid chromatography (IP-HPLC). The administration of 4HR (1-100 µM) showed significant HDACi activity (p < 0.05). Body weight was significantly different in male rats (p < 0.05), and mandibular size was significantly smaller in 4HR-treated male rats with reduced testosterone levels. However, the mandibular size was significantly higher in 4HR treated female rats with increased growth hormone levels. In conclusion, 4HR had HDACi activity in Saos-2 cells. The administration of 4HR on growing rats showed different responses in body weight and mandibular size between sexes.


Asunto(s)
Antihelmínticos/farmacología , Huesos/citología , Huesos Faciales/crecimiento & desarrollo , Hexilresorcinol/farmacología , Desarrollo Maxilofacial/efectos de los fármacos , Osteoblastos/citología , Animales , Huesos/efectos de los fármacos , Huesos Faciales/efectos de los fármacos , Femenino , Masculino , Osteoblastos/efectos de los fármacos , Ratas
7.
Bull Exp Biol Med ; 171(4): 458-460, 2021 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-34542762

RESUMEN

High efficiency of a combined preparation including synergistic polymyxin B and 4-hexylresorcinol was shown for treatment of experimental sepsis caused by an antibiotic-resistant highly virulent hypermucoid Klebsiella pneumoniae strain KPM9Pmr in mice. Complex therapy with polymyxin B (1 mg/kg) and 4-hexylresorcinol (30 mg/kg) led to cure in 80%; in 20% of these mice, no bacterial cells were found. After treatment with polymyxin B alone, only 50% animals survived and all of them contained bacterial cells. Comparative analysis of the results of monotherapy and combined treatment indicates that 4-hexylresorcinol not only increases the efficiency of antibiotic, but also minimizes persistence of the infection agent and therefore, the risk of development of antibiotic resistance.


Asunto(s)
Antibacterianos/uso terapéutico , Farmacorresistencia Bacteriana Múltiple/efectos de los fármacos , Hexilresorcinol/farmacología , Klebsiella pneumoniae/efectos de los fármacos , Sepsis/tratamiento farmacológico , Animales , Animales no Consanguíneos , Antibacterianos/farmacología , Modelos Animales de Enfermedad , Sinergismo Farmacológico , Femenino , Infecciones por Klebsiella/complicaciones , Infecciones por Klebsiella/tratamiento farmacológico , Infecciones por Klebsiella/patología , Klebsiella pneumoniae/patogenicidad , Ratones , Pruebas de Sensibilidad Microbiana , Polimixina B/farmacología , Polimixina B/uso terapéutico , Polimixinas/análogos & derivados , Polimixinas/farmacología , Polimixinas/uso terapéutico , Sepsis/microbiología
8.
Int J Mol Sci ; 21(4)2020 Feb 24.
Artículo en Inglés | MEDLINE | ID: mdl-32102282

RESUMEN

Surgical methods for accelerating orthodontic tooth movement are limited by possible damage to the tooth root and patient discomfort. 4-Hexylresorcinol (4HR) has been shown to increase bone remodeling and may potentially facilitate tooth movement. This study investigated the (1) effect of 4HR administration on osteoblast-like cells and (2) effect of 4HR administration on tooth movement in ovariectomized rats. Saos-2 cells were treated with either 4HR or solvent (control). Protein expression levels were investigated 2, 8, and 24 h after treatment. Thirty ovariectomized Sprague-Dawley rats were divided into two experimental groups (A and B) and one control group. After installation of an orthodontic tooth movement device, groups A and B received subcutaneous weekly injections of 4HR (1.28 and 128 mg/kg). Micro-computerized tomography and histological analyses were performed after 2 weeks of tooth movement. The application of 4HR elevated expression of osteogenic markers in Saos-2 cells. Movement of the first molars was significantly greater in rats administered 4HR. Furthermore, the expression of bone morphogenic protein-2, receptor activator of nuclear factor kappa-B ligand, osteocalcin, and tartrate-resistant acid phosphatase were increased after 4HR administration. 4HR application demonstrated increased expression of osteogenic markers in Saos-2 cells and accelerated orthodontic tooth movement in rats.


Asunto(s)
Hexilresorcinol/farmacología , Osteogénesis/efectos de los fármacos , Ovariectomía , Técnicas de Movimiento Dental/métodos , Animales , Biomarcadores/sangre , Línea Celular Tumoral , Ensayo de Inmunoadsorción Enzimática , Hexilresorcinol/administración & dosificación , Humanos , Masculino , Persona de Mediana Edad , Osteocalcina/sangre , Osteocalcina/metabolismo , Osteopontina/sangre , Osteopontina/metabolismo , Ratas Sprague-Dawley , Factor de Crecimiento Transformador beta1/sangre , Factor de Crecimiento Transformador beta1/metabolismo
9.
J Craniofac Surg ; 29(7): 1983-1990, 2018 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-29561490

RESUMEN

OBJECTIVE: The objectives of this study were to evaluate the suppression of the nuclear factor kappa B (NF-kB) pathway by 4-hexylresorcinol (4HR), which was activated by tumor necrosis factor-α (TNF-α) in osteoblasts, and new bone formation by 4HR-incorporated porcine bone in an animal model. STUDY DESIGN: For the confirmation of successful incorporation of 4HR into porcine bone, scanning electron microscopy (SEM) and Fourier transform-infrared (FT-IR) analysis were performed. High performance liquid chromatography was performed for the analysis of the 4HR release profile from porcine bone. MC 3T3-E1 cells were used for the analysis of the NF-kB signaling pathway activation by western blotting and real-time reverse transcriptase polymerase chain reaction. New bone formation and the analysis of marker protein expression were studied in a rat calvarial critical-sized defect model. RESULTS: Both SEM and FT-IR analysis demonstrated successful incorporation of 4HR into porcine bone. Approximately 30% of 4HR was steadily released from porcine bone for 18 days. 4HR suppressed the NF-kB signaling pathway, which was activated by TNF-α application in MC 3T3-E1 cells. Histological analysis revealed that porcine bone particles with incorporated 4HR showed significantly greater new bone formation than those without 4HR at 4 and 8 weeks after operation (P < 0.05). The expression intensities of alkaline phosphatase, osteoprotegerin, and osteocalcin were also higher in the 4HR-incorporated group. CONCLUSION: The application of 4HR suppressed the NF-kB signaling pathway in osteoblasts and 4HR-containing porcine bone particles promoted new bone formation in a rat calvarial defect model.


Asunto(s)
Hexilresorcinol/farmacología , FN-kappa B/metabolismo , Osteogénesis/efectos de los fármacos , Transducción de Señal/efectos de los fármacos , Células 3T3 , Fosfatasa Alcalina/metabolismo , Animales , Western Blotting , Masculino , Ratones , Modelos Animales , Osteoblastos/efectos de los fármacos , Osteocalcina/metabolismo , Osteoprotegerina/metabolismo , Ratas , Espectroscopía Infrarroja por Transformada de Fourier , Porcinos , Factor de Necrosis Tumoral alfa/metabolismo
10.
Molecules ; 23(9)2018 Aug 29.
Artículo en Inglés | MEDLINE | ID: mdl-30158429

RESUMEN

A method for the rapid determination of 4-hexylresorcinol (4-HR) residue in shrimp by solid phase extraction (SPE) ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was established. 4-HR was extracted twice with methanol, and the extract was formulated into methanol-water solution (1:1). After being cleaned up and concentrated by a PRIME HLB solid phase extraction column, the sample was analyzed by UPLC-MS/MS and quantitatively determined by an external standard method. The separation was performed with a gradient system consisting of water and acetonitrile as the mobile phase. Monitoring was performed by electrospray ionization (ESI) in negative ion mode using multiple ion reaction monitoring (MRM). Good linearity was obtained in the concentration range of 1.0⁻100.0 µg/L, with correlation coefficients larger than 0.999. The limit of detection (LOD) was 0.25 µg/kg and the limit of quantification (LOQ) was 0.80 µg/kg. The average recoveries of 4-HR at spiked concentrations of 2.40, 6.40 and 16 µg/kg ranged from 81.35% to 94.68% with the relative standard deviations (n = 6) from 3.57% to 6.86%. The results showed that the method is simple, fast, sensitive, reliable, and reproducible; thus, it could be used as a rapid confirmation and quantitative analysis method of 4-HR residue in aquatic products.


Asunto(s)
Antihelmínticos/análisis , Crustáceos/química , Hexilresorcinol/análisis , Animales , Antihelmínticos/química , Cromatografía Líquida de Alta Presión , Monitoreo del Ambiente , Hexilresorcinol/química , Límite de Detección , Extracción en Fase Sólida , Espectrometría de Masas en Tándem
11.
J Craniofac Surg ; 28(4): e392-e395, 2017 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-28590396

RESUMEN

PURPOSE: The objective of this study was to evaluate whether silk fibroin (SF) incorporated into 4-hexylresorcinol (4HR) could increase botulinum toxin-A (BTX-A) activity. MATERIAL AND METHODS: In total, 30 rats were used for this study. The animals were divided into 6 groups according to the injected materials (SA: saline only; SF; 4HR; B2: 2 units of BTX-A; B2 + SF + 4HR: combination of B2, SF, and 4HR; B5: 5 units of BTX-A). Serial sonography was used for the evaluation of muscle thickness after injection. Immunohistochemical staining was used for the evaluation of myosin type II (myo2) and Bcl-2 protein expression. RESULTS: The relative thickness of the masseter muscle in B2 group was 66.14% ±â€Š4.55% to the preinjection level; in B2 + SF + 4HR group was 54.59% ±â€Š4.83%, and in B5 group was 56.19% ±â€Š8.28%. Any BTX-injected group showed significantly lower value of the relative muscle thickness compared to SA, SF, or 4HR group (P < 0.001 for all). The difference of relative muscle thickness between B2 group and B2 + SF + 4HR group was statistically significant (P < 0.001). The intensity of myo2 immunostaining in B5, B2, and B2 + SF + 4HR group was significantly higher than those in the other groups (P < 0.05). CONCLUSIONS: When 2 units of BTX was incorporated to SF and 4HR, combination formula showed similar activity to those of 5 units of BTX.


Asunto(s)
Antihelmínticos/administración & dosificación , Toxinas Botulínicas Tipo A/administración & dosificación , Fibroínas/administración & dosificación , Hexilresorcinol/administración & dosificación , Músculo Masetero/efectos de los fármacos , Fármacos Neuromusculares/administración & dosificación , Animales , Inyecciones Intramusculares , Músculo Masetero/patología , Ratas
12.
J Drugs Dermatol ; 15(7): 863-8, 2016 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-27391637

RESUMEN

Consumers are increasingly interested in over-the-counter skin care products that can improve the appearance of photodamaged and aging skin. This 10-week, open-label, single- center study enrolled 25 subjects with mild to moderate hyperpigmentation and other clinical stigmata of cutaneous aging including fine lines, sallowness, lack of clarity, and wrinkling. Their mean age was 53.4±7.7 years. The test product contained retinol 0.5% in combination with niacinamide 4.4%, resveratrol 1%, and hexylresorcinol 1.1% in a moisturizing base. Subjects were provided a skin care regimen including a cleanser, hydrating serum, moisturizer, and an SPF 30 sunscreen for daily use. The test product was applied only at night.

The use of this skin brightening/anti-aging cosmeceutical was found to provide statistically significant improvements in all efficacy endpoints by study end. Fine lines, radiance, and smoothness were significantly improved as early as week 2 (P<.001). By week 4, hyperpigmentation, overall skin clarity, evenness of skin tone, and wrinkles showed statistically significant improvement compared to baseline. Mild retinoid dermatitis including flaking and redness occurred early in the study as reflected by tolerability scores. By week 10, subjects reported no stinging, itching, dryness, or tingling.

The results of this open-label clinical study suggest that a topical cream containing retinol 0.5% in combination with niacinamide, resveratrol, and hexylresorcinol is efficacious and tolerable for skin brightening/anti-aging when used with a complementary skin care regimen including SPF 30 sun protection.

J Drugs Dermatol. 2016;15(7):863-868.


Asunto(s)
Cosmecéuticos/administración & dosificación , Hexilresorcinol/administración & dosificación , Niacinamida/administración & dosificación , Envejecimiento de la Piel/efectos de los fármacos , Estilbenos/administración & dosificación , Vitamina A/administración & dosificación , Administración Cutánea , Cosmecéuticos/efectos adversos , Combinación de Medicamentos , Erupciones por Medicamentos/diagnóstico , Erupciones por Medicamentos/etiología , Femenino , Hexilresorcinol/efectos adversos , Humanos , Persona de Mediana Edad , Niacinamida/efectos adversos , Resveratrol , Envejecimiento de la Piel/patología , Cuidados de la Piel/métodos , Pigmentación de la Piel/efectos de los fármacos , Estilbenos/efectos adversos , Encuestas y Cuestionarios , Resultado del Tratamiento , Vitamina A/efectos adversos
13.
Tumour Biol ; 34(3): 1595-603, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23412976

RESUMEN

The present study was undertaken to examine the effects of cisplatin plus 4-hexylresorcinol (4-HR) combination therapy on oral mucosal melanoma (OMM) using cultured primary OMM cells in a tumour xenograft model. Cultured primary OMM cells were used for the MTT assay and DNA microarray. OMM cells were implanted into the submandibular glands of nude mice. The mice were then treated with cisplatin only or cisplatin plus 4-HR. Tumour size changes, survival rate and tumour metastasis were compared between the two groups by observation, micro-positron emission tomography (PET) and histological examination. In the MTT assay, the cisplatin plus 4-HR group showed significantly higher inhibition of OMM cell growth compared to the other groups (p<0.05). DNA microarray results showed significant inhibition of matrix metalloproteinase (MMP)-2 gene expression upon 4-HR application. The necropsy and micro-PET results showed that the mice from the cisplatin-only group had more distant metastases than the mice from the cisplatin plus 4-HR combination group (p=0.002). MMP-2 expression was lower in the primary tumours in the cisplatin plus 4-HR combination group than in the cisplatin-only group (p<0.001). Overall survival was longer in mice from the cisplatin plus 4-HR combination group than in the cisplatin-only group (p=0.049). In conclusion, the combined effect of cisplatin and 4-HR resulted in fewer metastases and longer survival than cisplatin-only treatment in the OMM xenograft model.


Asunto(s)
Apoptosis/efectos de los fármacos , Proliferación Celular/efectos de los fármacos , Cisplatino/farmacología , Modelos Animales de Enfermedad , Hexilresorcinol/farmacología , Melanoma Experimental/mortalidad , Neoplasias de la Boca/mortalidad , Animales , Antihelmínticos/farmacología , Antineoplásicos/farmacología , Protocolos de Quimioterapia Combinada Antineoplásica , Biomarcadores de Tumor/genética , Biomarcadores de Tumor/metabolismo , Sinergismo Farmacológico , Perfilación de la Expresión Génica , Humanos , Técnicas para Inmunoenzimas , Masculino , Melanoma Experimental/tratamiento farmacológico , Melanoma Experimental/patología , Ratones , Ratones Desnudos , Mucosa Bucal/efectos de los fármacos , Mucosa Bucal/patología , Neoplasias de la Boca/tratamiento farmacológico , Neoplasias de la Boca/patología , Análisis de Secuencia por Matrices de Oligonucleótidos , Células Tumorales Cultivadas , Ensayos Antitumor por Modelo de Xenoinjerto
14.
J Craniofac Surg ; 24(6): 1927-30, 2013 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-24220375

RESUMEN

The objective of this study was to demonstrate that a silk fibroin (SF) and 4-hexylresorcinol (4-HR) incorporation membrane could be used for a guided bone regeneration technique. Fourier transform infrared measurements were obtained to determine change of physical property of SF membrane by 4-HR incorporation. Two peri-implant defects, 3.0 × 5.0 mm (width × length), were prepared on the lateral side of the implant hole in the tibia of New Zealand white rabbits (n = 8). The peri-implant defect was left unfilled in the control group. Silk fibroin + 4-HR membrane was applied to the peri-implant defect in the experimental group. The 8 animals were killed at 8 weeks after implantation. Subsequently, removal torque test and histomorphometric evaluation were done. Fourier transform infrared spectroscopy showed no specific chemical interaction between 4-HR and SF. In the histomorphometric analysis, the mean bone regeneration was 18.3 ± 1.9 mm(2) in the experimental group and 9.3 ± 0.9 mm(2) in the control group (P = 0.004). In conclusion, the SF and 4-HR incorporation membrane successfully regenerated bone in the rabbit tibia peri-implant bone defect model.


Asunto(s)
Regeneración Ósea/fisiología , Fibroínas/uso terapéutico , Regeneración Tisular Dirigida/instrumentación , Hexilresorcinol/uso terapéutico , Membranas Artificiales , Animales , Enfermedades Óseas/patología , Enfermedades Óseas/terapia , Implantación Dental Endoósea/métodos , Implantes Dentales , Fibroínas/química , Hexilresorcinol/química , FN-kappa B/antagonistas & inhibidores , Osteogénesis/fisiología , Conejos , Seda , Espectroscopía Infrarroja por Transformada de Fourier , Tibia/patología , Tibia/cirugía , Factores de Tiempo , Torque
15.
Int J Biol Macromol ; 237: 124212, 2023 May 15.
Artículo en Inglés | MEDLINE | ID: mdl-36977442

RESUMEN

To augment the functional attributes of pectin and expand its prospective utilization in food preservation, this research explored the enzymatic grafting of resorcinol and 4-hexylresorcinol onto pectin. Structural analysis verified the successful grafting of both resorcinol and 4-hexylresorcinol to pectin via esterification, with the 1-OH of resorcinol and 4-hexylresorcinol and the carboxyl group of pectin functioning as grafting sites. The grafting ratios of resorcinol-modified pectin (Re-Pe) and 4-hexylresorcinol-modified pectin (He-Pe) were 17.84 % and 10.98 %, respectively. This grafting modification notably enhanced the antioxidative and antibacterial properties of pectin. Specifically, DPPH clearance and the inhibition ratio in the ß-carotene bleaching assay increased from 11.38 % and 20.13 % (native pectin, Na-Pe) to 41.15 % and 36.67 % (Re-Pe), and 74.72 % and 53.40 % (He-Pe). Moreover, the inhibition zone diameter against Escherichia coli and Staphylococcus aureus rose from 10.12 and 10.08 mm (Na-Pe) to 12.36 and 11.52 mm (Re-Pe), and 16.78 and 14.87 mm (He-Pe). Additionally, the application of native and modified pectin coatings effectively impeded pork spoilage, with the modified pectins demonstrating a more potent effect. Among the two modified pectins, He-Pe exhibited the most significant enhancement in pork shelf life.


Asunto(s)
Hexilresorcinol , Pectinas , Pectinas/química , Hexilresorcinol/farmacología , Estudios Prospectivos , Conservación de Alimentos , Carne , Escherichia coli
16.
Arch Dermatol Res ; 315(5): 1207-1214, 2023 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-36502500

RESUMEN

Dyspigmentation is a common cosmetic concern in dermatology. Currently, the first line topical medication in the United States is hydroquinone. Hydroquinone use is associated with potential safety concerns including cytotoxicity to melanocytes, systemic absorption, metabolism in distant organs, and production of potentially carcinogenic metabolites. Hexylresorcinol is an ingredient that has been used in food preservation and as antiseptic has been shown to inhibit tyrosinase in vitro and has been studied as a novel skin-lightening agent. To perform a double-blind randomized split-body investigation of comparison on topical hexylresorcinol and hydroquinone on face and hands to assess for change in the appearance of skin tone and pigmentation. Thirty-two healthy female participants ages 35-65 (50.93 ± 7.37) years old with skin type I-IV were randomized to using either topical 1% hexylresorcinol or 2% hydroquinone on the left or right side of the face and corresponding hand over 12 weeks. The topical preparation was applied twice a day to assigned areas. Standardized photos were taken of the face and colorimetric measurements were taken of both sides of the forehead, cheeks and each hand at baseline (Day 0), week 4, and week 12. Of the 32 participants, 3 were lost to follow-up and the remaining were included in the final analysis. Pigmentation measured by colorimeter and clinical grading were significantly decreased at 4 and 12 weeks relative to baseline with no difference between the HR and HQ groups. No adverse effects were noted with either intervention. Hexylresorcinol 1% is well-tolerated and equivalent to hydroquinone 2% in reducing the appearance of facial and hand pigment. Further studies with an expanded population and longer time course are warranted.Registration No.: NCT04345094.


Asunto(s)
Hexilresorcinol , Trastornos de la Pigmentación , Humanos , Femenino , Adulto , Persona de Mediana Edad , Resultado del Tratamiento , Hidroquinonas/efectos adversos , Estudios Prospectivos , Método Doble Ciego
17.
J Pharm Pharm Sci ; 15(2): 281-94, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-22579007

RESUMEN

PURPOSE: Sore throat is a frequent reason for seeking medical care but few prescription options are available. Lozenges are effective in delivering active ingredients to the throat. This study was conducted to determine the analgesic efficacy of two lozenges one containing amylmetacresol (AMC)/2,4-dichlorobenzyl alcohol (DCBA) and lidocaine and one containing hexylresorcinol  versus placebo in patients with acute sore throat due to upper respiratory tract infection (URTI). METHODS: This was a multicentre, randomised, double-blind, parallel group, placebo-controlled study. In total, 190 patients were randomised 1:1:1 to a single dose of AMC/DCBA + lidocaine, hexylresorcinol or placebo lozenge. Subjective ratings of throat soreness, difficulty swallowing, swollen throat, numbing, and sore throat relief were obtained up to 2 hours post dose. Patient and investigator global ratings and a consumer questionnaire were also collected. The primary endpoint was the change from baseline in severity of throat soreness for both lozenges versus placebo at 2 hours post dose. RESULTS: The hexylresorcinol lozenge demonstrated superiority over placebo for primary and secondary efficacy variables including those related to throat soreness, sore throat relief and difficulty swallowing; the AMC/DCBA + lidocaine lozenge was also superior to placebo for secondary endpoints at various time points but did not reach significance for the primary efficacy variable. Both lozenges had a rapid onset of action from 1-10 minutes post dose for the AMC/DCBA + lidocaine lozenge and 1-5 minutes post dose for the hexylresorcinol lozenge. Numbness was reported from 1 minute post dose with the AMC/DCBA + lidocaine lozenge and was greatest at 15 minutes. Numbness was reported from 5 minutes post dose with the hexylresorcinol lozenge and was greatest at 10 minutes. Both lozenges were well tolerated. CONCLUSIONS: Both AMC/DCBA + lidocaine and hexylresorcinol lozenges provided rapid and effective sore throat relief in patients with URTI.


Asunto(s)
Anestésicos Locales/administración & dosificación , Antiinfecciosos Locales/administración & dosificación , Alcoholes Bencílicos/administración & dosificación , Cresoles/administración & dosificación , Hexilresorcinol/administración & dosificación , Lidocaína/administración & dosificación , Faringitis/tratamiento farmacológico , Adolescente , Adulto , Anciano , Método Doble Ciego , Combinación de Medicamentos , Femenino , Humanos , Masculino , Persona de Mediana Edad , Faringitis/etiología , Infecciones del Sistema Respiratorio/complicaciones , Infecciones del Sistema Respiratorio/tratamiento farmacológico , Adulto Joven
18.
Molecules ; 17(5): 5126-38, 2012 May 03.
Artículo en Inglés | MEDLINE | ID: mdl-22555300

RESUMEN

Antioxidant activity of a number of small (low molecular weight) natural compounds found in spices, condiments or drugs (gallic acid, sesamol, eugenol, thymol, carvacrol, vanillin, salicylaldehyde, limonene, geraniol, 4-hexylresorcinol, etc.) has been evaluated using electrochemical and DPPH• radical scavenging measurements. Structural analysis of the tested compound suggest a remarkable activity for phenol derivatives and the importance of the -R groups located on the phenolic ring in the molecule's ability to act as free radical scavenging as well as their influence in the electrochemical behavior. The voltammetric method can be used for the determination of the antioxidant capability in the same manner as the DPPH• radical scavenging because of the correlation found between oxidation potentials and anti-radical power (ARP = 1/EC50). Such electrochemical determination is fast and cheap and allows making measurements under a variety of experimental conditions. The accuracy of the electrochemical measurements is the same for all the compounds, irrespective of their scavenging activity, the opposite of what occurs in the DPPH• test.


Asunto(s)
Antioxidantes/química , Compuestos de Bifenilo/antagonistas & inhibidores , Técnicas Electroquímicas , Radicales Libres/antagonistas & inhibidores , Picratos/antagonistas & inhibidores , Monoterpenos Acíclicos , Aldehídos/química , Benzaldehídos/química , Benzodioxoles/química , Condimentos , Ciclohexenos/química , Cimenos , Eugenol/química , Ácido Gálico/química , Hexanos/química , Hexilresorcinol , Limoneno , Monoterpenos/química , Oxidación-Reducción , Fenoles/química , Medicamentos bajo Prescripción , Resorcinoles/química , Especias , Terpenos/química , Timol/química
19.
Pharm Dev Technol ; 17(6): 705-11, 2012.
Artículo en Inglés | MEDLINE | ID: mdl-21554190

RESUMEN

The unstirred aqueous boundary layer (ABL) thickness was determined for modified Franz diffusion cells using three test compounds--parathion, 4-hexylresorcinol, and 2,4-dinitrochlorobenzene (DNCB). Steady-state fluxes through one, two, and three dialysis membranes in series were achieved in donor-saturated, infinite-dose permeation experiments. These results were then used to calculate the total diffusive resistance for each case, as well as an extrapolated zero membrane value which was used in conjunction with an estimate of the aqueous diffusivities to calculate the ABL thickness. The resulting value (mean ± SE) was 0.070 ± 0.004 cm.


Asunto(s)
Dinitroclorobenceno/química , Hexilresorcinol/química , Membranas Artificiales , Paratión/química , Agua/química , Diálisis/métodos , Difusión , Modelos Biológicos , Permeabilidad
20.
Mol Gen Mikrobiol Virusol ; (1): 25-9, 2012.
Artículo en Ruso | MEDLINE | ID: mdl-22702141

RESUMEN

An increase in the nitric oxide (NO) biosynthesis in Lactobacillus plantarum 8P-A3 cells takes place under strong stress influence, which leads to a considerable decrease in the microbial cell viability: heating at 70 degrees C and 80 degrees C, prolonged cultivation, toxic effect of hexylresorcinol. The factors, which do not lead to cell death, such as heating at 60 degrees C, 50 microg/ml homoserine lactone, Bacillus intermedius 7P ribonuclease (binase) in concentrations up to 300 microg/ml, do not induce NO synthesis. The activation of the NO biosynthesis in response to stress treatment evidences to universality of key-mechanisms of stress response in cells differing in the level of their organization as well as to important role of nitric oxide in them.


Asunto(s)
Supervivencia Celular/efectos de los fármacos , Lactobacillus plantarum/metabolismo , Óxido Nítrico/biosíntesis , Óxido Nítrico/metabolismo , 4-Butirolactona/administración & dosificación , Endorribonucleasas/administración & dosificación , Activación Enzimática/efectos de los fármacos , Hexilresorcinol/administración & dosificación , Óxido Nítrico Sintasa/metabolismo , Estrés Fisiológico , Temperatura
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA